The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Needle Free Diabetes Management Market Research Report 2025
Synopsis
The global Needle Free Diabetes Management market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.
Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
This report aims to provide a comprehensive presentation of the global market for Needle Free Diabetes Management, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Needle Free Diabetes Management.
Report Scope
The Needle Free Diabetes Management market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Needle Free Diabetes Management market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Needle Free Diabetes Management companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Zogenix
3M
Antares Pharma Inc.
Glide Pharmaceutical Technologies
Injex Pharma AG
Pharmajet, Inc.
Bioject Medical Technologies
Medtronic
Johnson & Johnson
Pancreum LLC
Tandem Diabetes Care
JDRF
Akra Dermojet
Segment by Type
Insulin Jet Injector
Insulin Pen
Insulin Inhaler
Insulin Patch & Pump
Segment by Application
Hospitals
Clinics
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Needle Free Diabetes Management companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Needle Free Diabetes Management market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.
Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
This report aims to provide a comprehensive presentation of the global market for Needle Free Diabetes Management, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Needle Free Diabetes Management.
Report Scope
The Needle Free Diabetes Management market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Needle Free Diabetes Management market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Needle Free Diabetes Management companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Zogenix
3M
Antares Pharma Inc.
Glide Pharmaceutical Technologies
Injex Pharma AG
Pharmajet, Inc.
Bioject Medical Technologies
Medtronic
Johnson & Johnson
Pancreum LLC
Tandem Diabetes Care
JDRF
Akra Dermojet
Segment by Type
Insulin Jet Injector
Insulin Pen
Insulin Inhaler
Insulin Patch & Pump
Segment by Application
Hospitals
Clinics
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Needle Free Diabetes Management companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Needle Free Diabetes Management Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Insulin Jet Injector
1.2.3 Insulin Pen
1.2.4 Insulin Inhaler
1.2.5 Insulin Patch & Pump
1.3 Market by Application
1.3.1 Global Needle Free Diabetes Management Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Needle Free Diabetes Management Market Perspective (2019-2030)
2.2 Needle Free Diabetes Management Growth Trends by Region
2.2.1 Global Needle Free Diabetes Management Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Needle Free Diabetes Management Historic Market Size by Region (2019-2024)
2.2.3 Needle Free Diabetes Management Forecasted Market Size by Region (2025-2030)
2.3 Needle Free Diabetes Management Market Dynamics
2.3.1 Needle Free Diabetes Management Industry Trends
2.3.2 Needle Free Diabetes Management Market Drivers
2.3.3 Needle Free Diabetes Management Market Challenges
2.3.4 Needle Free Diabetes Management Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Needle Free Diabetes Management Players by Revenue
3.1.1 Global Top Needle Free Diabetes Management Players by Revenue (2019-2024)
3.1.2 Global Needle Free Diabetes Management Revenue Market Share by Players (2019-2024)
3.2 Global Needle Free Diabetes Management Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Needle Free Diabetes Management Revenue
3.4 Global Needle Free Diabetes Management Market Concentration Ratio
3.4.1 Global Needle Free Diabetes Management Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Needle Free Diabetes Management Revenue in 2023
3.5 Needle Free Diabetes Management Key Players Head office and Area Served
3.6 Key Players Needle Free Diabetes Management Product Solution and Service
3.7 Date of Enter into Needle Free Diabetes Management Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Needle Free Diabetes Management Breakdown Data by Type
4.1 Global Needle Free Diabetes Management Historic Market Size by Type (2019-2024)
4.2 Global Needle Free Diabetes Management Forecasted Market Size by Type (2025-2030)
5 Needle Free Diabetes Management Breakdown Data by Application
5.1 Global Needle Free Diabetes Management Historic Market Size by Application (2019-2024)
5.2 Global Needle Free Diabetes Management Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Needle Free Diabetes Management Market Size (2019-2030)
6.2 North America Needle Free Diabetes Management Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Needle Free Diabetes Management Market Size by Country (2019-2024)
6.4 North America Needle Free Diabetes Management Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Needle Free Diabetes Management Market Size (2019-2030)
7.2 Europe Needle Free Diabetes Management Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Needle Free Diabetes Management Market Size by Country (2019-2024)
7.4 Europe Needle Free Diabetes Management Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Needle Free Diabetes Management Market Size (2019-2030)
8.2 Asia-Pacific Needle Free Diabetes Management Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Needle Free Diabetes Management Market Size by Region (2019-2024)
8.4 Asia-Pacific Needle Free Diabetes Management Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Needle Free Diabetes Management Market Size (2019-2030)
9.2 Latin America Needle Free Diabetes Management Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Needle Free Diabetes Management Market Size by Country (2019-2024)
9.4 Latin America Needle Free Diabetes Management Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Needle Free Diabetes Management Market Size (2019-2030)
10.2 Middle East & Africa Needle Free Diabetes Management Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Needle Free Diabetes Management Market Size by Country (2019-2024)
10.4 Middle East & Africa Needle Free Diabetes Management Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Zogenix
11.1.1 Zogenix Company Detail
11.1.2 Zogenix Business Overview
11.1.3 Zogenix Needle Free Diabetes Management Introduction
11.1.4 Zogenix Revenue in Needle Free Diabetes Management Business (2019-2024)
11.1.5 Zogenix Recent Development
11.2 3M
11.2.1 3M Company Detail
11.2.2 3M Business Overview
11.2.3 3M Needle Free Diabetes Management Introduction
11.2.4 3M Revenue in Needle Free Diabetes Management Business (2019-2024)
11.2.5 3M Recent Development
11.3 Antares Pharma Inc.
11.3.1 Antares Pharma Inc. Company Detail
11.3.2 Antares Pharma Inc. Business Overview
11.3.3 Antares Pharma Inc. Needle Free Diabetes Management Introduction
11.3.4 Antares Pharma Inc. Revenue in Needle Free Diabetes Management Business (2019-2024)
11.3.5 Antares Pharma Inc. Recent Development
11.4 Glide Pharmaceutical Technologies
11.4.1 Glide Pharmaceutical Technologies Company Detail
11.4.2 Glide Pharmaceutical Technologies Business Overview
11.4.3 Glide Pharmaceutical Technologies Needle Free Diabetes Management Introduction
11.4.4 Glide Pharmaceutical Technologies Revenue in Needle Free Diabetes Management Business (2019-2024)
11.4.5 Glide Pharmaceutical Technologies Recent Development
11.5 Injex Pharma AG
11.5.1 Injex Pharma AG Company Detail
11.5.2 Injex Pharma AG Business Overview
11.5.3 Injex Pharma AG Needle Free Diabetes Management Introduction
11.5.4 Injex Pharma AG Revenue in Needle Free Diabetes Management Business (2019-2024)
11.5.5 Injex Pharma AG Recent Development
11.6 Pharmajet, Inc.
11.6.1 Pharmajet, Inc. Company Detail
11.6.2 Pharmajet, Inc. Business Overview
11.6.3 Pharmajet, Inc. Needle Free Diabetes Management Introduction
11.6.4 Pharmajet, Inc. Revenue in Needle Free Diabetes Management Business (2019-2024)
11.6.5 Pharmajet, Inc. Recent Development
11.7 Bioject Medical Technologies
11.7.1 Bioject Medical Technologies Company Detail
11.7.2 Bioject Medical Technologies Business Overview
11.7.3 Bioject Medical Technologies Needle Free Diabetes Management Introduction
11.7.4 Bioject Medical Technologies Revenue in Needle Free Diabetes Management Business (2019-2024)
11.7.5 Bioject Medical Technologies Recent Development
11.8 Medtronic
11.8.1 Medtronic Company Detail
11.8.2 Medtronic Business Overview
11.8.3 Medtronic Needle Free Diabetes Management Introduction
11.8.4 Medtronic Revenue in Needle Free Diabetes Management Business (2019-2024)
11.8.5 Medtronic Recent Development
11.9 Johnson & Johnson
11.9.1 Johnson & Johnson Company Detail
11.9.2 Johnson & Johnson Business Overview
11.9.3 Johnson & Johnson Needle Free Diabetes Management Introduction
11.9.4 Johnson & Johnson Revenue in Needle Free Diabetes Management Business (2019-2024)
11.9.5 Johnson & Johnson Recent Development
11.10 Pancreum LLC
11.10.1 Pancreum LLC Company Detail
11.10.2 Pancreum LLC Business Overview
11.10.3 Pancreum LLC Needle Free Diabetes Management Introduction
11.10.4 Pancreum LLC Revenue in Needle Free Diabetes Management Business (2019-2024)
11.10.5 Pancreum LLC Recent Development
11.11 Tandem Diabetes Care
11.11.1 Tandem Diabetes Care Company Detail
11.11.2 Tandem Diabetes Care Business Overview
11.11.3 Tandem Diabetes Care Needle Free Diabetes Management Introduction
11.11.4 Tandem Diabetes Care Revenue in Needle Free Diabetes Management Business (2019-2024)
11.11.5 Tandem Diabetes Care Recent Development
11.12 JDRF
11.12.1 JDRF Company Detail
11.12.2 JDRF Business Overview
11.12.3 JDRF Needle Free Diabetes Management Introduction
11.12.4 JDRF Revenue in Needle Free Diabetes Management Business (2019-2024)
11.12.5 JDRF Recent Development
11.13 Akra Dermojet
11.13.1 Akra Dermojet Company Detail
11.13.2 Akra Dermojet Business Overview
11.13.3 Akra Dermojet Needle Free Diabetes Management Introduction
11.13.4 Akra Dermojet Revenue in Needle Free Diabetes Management Business (2019-2024)
11.13.5 Akra Dermojet Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
